Testing Tumor and Blood to Guide Lung Cancer Treatment
This study is looking at how we can use information from your tumor tissue and blood to find personalized treatments for suspected early-stage lung cancers. Researchers will test for specific changes in your cancer cells, called "actionable oncogenic drivers" (like mutations in EGFR, KRAS G12C, or rearrangements in ALK, RET, ROS1). These changes can help doctors decide if you might benefit from certain targeted therapies. The study aims to see how many patients have these drivers, which could make them eligible for future treatment trials. You may be able to join if you have clinical stage IA2-III lung cancer that might be removed by surgery and no other cancers or prior lung cancer within the last two years. The study plans to enroll 1000 participants.
- Study design
- This is an observational study, meaning researchers will collect information without giving a specific treatment. It aims to enroll 1000 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goal is measured at 8 weeks, looking at the proportion of patients with actionable oncogenic drivers.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers
At a glance
Conditions
Where it's being run
21 sites across 13 statesStudy leadership
- Scott J Swanson, MD · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Proportion of Patients who Possess Actionable Oncogenic Drivers8 weeks
The primary outcome measure is the determination of the proportion of patients with stage IA2-III lung cancers who possess actionable oncogenic drivers. A patient is considered to have a actionable oncogenic driver if they have any of the following 10 genomic alterations: ALK rearrangements, BRAFV600E mutations, EGFR sensitizing mutations, HER2 mutation, HER2 amplification, MET amplification, MET exon 14 mutation, RET rearrangements, NTRK rearrangement, or ROS1 rearrangements.